AIM: The first hepatitis C virus (HCV) recombinant, RF2k/1b, was initially described from Russia and has since then been identified from patients in Ireland, Estonia, Uzbekistan and Cyprus. Many of these patients originated from Georgia; however, there is no information on its prevalence in Georgia or its susceptibility to antiviral treatment. METHODS: We retrospectively sequenced the non-structural region 5B (NS5B) of the HCV genome in samples from 72 Georgian patients, 36 of whom had been treated with pegylated interferon and ribavirin. RESULTS: The HCV genotype was determined using the Versant HCV Genotype v2 kit. Based on this typing, 32 patients (44.4%) were infected with genotype 1, 21 (29.1%) genotype 2 and 19 (26.3%) genotype 3. Partial NS5B of these strains was sequenced and analyzed for type, with concordant genotype results for all type 1 and 3 strains. Discrepant results were observed for genotyped 2 strains, with 16 (76%) having NS5B of subtype 1b. On phylogenetic analysis, 15 NS5B sequences of these strains were found in a clade formed by recombinant RF2k/1b strains. The remaining discordant sequence was found within a clade formed by 1b strains. CONCLUSION: Our findings show that the RF2k/1b recombinant strain is common among Georgian patients previously assumed to be infected with genotype 2. Because genotyping is mainly performed to decide treatment strategies, there is a need to determine the genotype by analysis of at least two genomic regions in strains from Georgian patients considered infected with genotype 2 based on standard HCV genotyping methods.
AIM: The first hepatitis C virus (HCV) recombinant, RF2k/1b, was initially described from Russia and has since then been identified from patients in Ireland, Estonia, Uzbekistan and Cyprus. Many of these patients originated from Georgia; however, there is no information on its prevalence in Georgia or its susceptibility to antiviral treatment. METHODS: We retrospectively sequenced the non-structural region 5B (NS5B) of the HCV genome in samples from 72 Georgian patients, 36 of whom had been treated with pegylated interferon and ribavirin. RESULTS: The HCV genotype was determined using the Versant HCV Genotype v2 kit. Based on this typing, 32 patients (44.4%) were infected with genotype 1, 21 (29.1%) genotype 2 and 19 (26.3%) genotype 3. Partial NS5B of these strains was sequenced and analyzed for type, with concordant genotype results for all type 1 and 3 strains. Discrepant results were observed for genotyped 2 strains, with 16 (76%) having NS5B of subtype 1b. On phylogenetic analysis, 15 NS5B sequences of these strains were found in a clade formed by recombinant RF2k/1b strains. The remaining discordant sequence was found within a clade formed by 1b strains. CONCLUSION: Our findings show that the RF2k/1b recombinant strain is common among Georgian patients previously assumed to be infected with genotype 2. Because genotyping is mainly performed to decide treatment strategies, there is a need to determine the genotype by analysis of at least two genomic regions in strains from Georgian patients considered infected with genotype 2 based on standard HCV genotyping methods.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Eric Lawitz; Jay P Lalezari; Tarek Hassanein; Kris V Kowdley; Fred F Poordad; Aasim M Sheikh; Nezam H Afdhal; David E Bernstein; Edwin Dejesus; Bradley Freilich; David R Nelson; Douglas T Dieterich; Ira M Jacobson; Donald Jensen; Gary A Abrams; Jama M Darling; Maribel Rodriguez-Torres; K Rajender Reddy; Mark S Sulkowski; Natalie H Bzowej; Robert H Hyland; Hongmei Mo; Ming Lin; Michael Mader; Robert Hindes; Efsevia Albanis; William T Symonds; Michelle M Berrey; Andrew Muir Journal: Lancet Infect Dis Date: 2013-03-15 Impact factor: 25.071
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato Journal: N Engl J Med Date: 1996-01-11 Impact factor: 91.245
Authors: Tatjana Tallo; Helene Norder; Valentina Tefanova; Tõnu Krispin; Jelena Schmidt; Madis Ilmoja; Karen Orgulas; Kaije Pruunsild; Ludmilla Priimägi; Lars O Magnius Journal: J Med Virol Date: 2007-04 Impact factor: 2.327
Authors: Johannes Vermehren; Christoph Sarrazin; Kai-Henrik Peiffer; Lisa Kuhnhenn; Evelyn Stelzl; Julia Dietz; Simone Susser; Andrea Oliver Tal; Fabian Finkelmeier; Eli Zuckerman; Marcus Cornberg; Mira Barak; Valeria Piazzolla; Alessandra Mangia; Stefan Zeuzem; Harald H Kessler Journal: J Clin Microbiol Date: 2019-06-25 Impact factor: 5.948
Authors: Tania M Welzel; David R Nelson; Giuseppe Morelli; Adrian Di Bisceglie; Rajender K Reddy; Alexander Kuo; Joseph K Lim; Jama Darling; Paul Pockros; Joseph S Galati; Lynn M Frazier; Saleh Alqahtani; Mark S Sulkowski; Monika Vainorius; Lucy Akushevich; Michael W Fried; Stefan Zeuzem Journal: Gut Date: 2016-07-13 Impact factor: 23.059
Authors: Matthew W McClure; Elina Berliba; Tengiz Tsertsvadze; Adrian Streinu-Cercel; Leen Vijgen; Béatrice Astruc; Alain Patat; Christopher Westland; Sushmita Chanda; Qingling Zhang; Thomas N Kakuda; Jennifer Vuong; Nick Khorlin; Leonid Beigelman; Lawrence M Blatt; John Fry Journal: PLoS One Date: 2018-10-16 Impact factor: 3.240
Authors: Magda Bletsa; Bram Vrancken; Sophie Gryseels; Ine Boonen; Antonios Fikatas; Yiqiao Li; Anne Laudisoit; Sebastian Lequime; Josef Bryja; Rhodes Makundi; Yonas Meheretu; Benjamin Dudu Akaibe; Sylvestre Gambalemoke Mbalitini; Frederik Van de Perre; Natalie Van Houtte; Jana Těšíková; Elke Wollants; Marc Van Ranst; Oliver G Pybus; Jan Felix Drexler; Erik Verheyen; Herwig Leirs; Joelle Gouy de Bellocq; Philippe Lemey Journal: Virus Evol Date: 2021-04-12